Pcn17 - Indirect Treatment Comparisons of Nivolumab Versus Regorafenib, Cabozantinib and Best Supportive Care After Treatment With Sorafenib for Hepatocellular Carcinoma
Value in Health- United Kingdom
doi 10.1016/j.jval.2018.09.099
Full Text
Abstract
Available in
Date
October 1, 2018
Authors
Publisher
Elsevier BV